Market capitalization | $553.99m |
Enterprise Value | $549.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.55 |
P/S ratio (TTM) P/S ratio | 4.59 |
P/B ratio (TTM) P/B ratio | 4.69 |
Revenue growth (TTM) Revenue growth | -7.49% |
Revenue (TTM) Revenue | $120.82m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a Surmodics Inc forecast:
3 Analysts have issued a Surmodics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 121 121 |
7%
7%
|
|
Gross Profit | 86 86 |
17%
17%
|
|
EBITDA | 1.58 1.58 |
85%
85%
|
EBIT (Operating Income) EBIT | -7.48 -7.48 |
619%
619%
|
Net Profit | -1.40 -1.40 |
94%
94%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.
Head office | United States |
CEO | Gary Maharaj |
Employees | 376 |
Founded | 1979 |
Website | www.surmodics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.